{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T21:14:05Z","timestamp":1769634845705,"version":"3.49.0"},"reference-count":16,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2020,8,28]],"date-time":"2020-08-28T00:00:00Z","timestamp":1598572800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"National Institute of Health and Medical Research Center for Clinical Multidisciplinary Research, INSERM U1116, Universit\u00e9 de Lorraine"},{"name":"Lucien Award Research Grant"},{"name":"Ablative Solutions"},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Corvidia"},{"name":"CVRx"},{"name":"Fresenius"},{"name":"Grunenthal"},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"name":"NovoNordisk"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,4,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Aims<\/jats:title>\n                  <jats:p>Among patients with acute myocardial infarction (AMI) complicated by heart failure [HF; clinical HF or left ventricular (LV) systolic dysfunction], we explored the probability of subsequent non-fatal cardiovascular (CV) events and sudden cardiac death (SCD).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods and results<\/jats:title>\n                  <jats:p>The high-risk myocardial infarction (HRMI) database contains 28\u00a0771 patients with signs of HF or reduced LV ejection fraction (&amp;lt;40%) after AMI. We evaluated the temporal association between SCD with preceding non-fatal CV event [HF hospitalization, recurrent myocardial infarction (MI), or stroke]. Median follow-up was 1.9 years. Mean age was 65.0\u2009\u00b1\u200911.5 years and 70% were male. The incidence of CV death was 7.9 per 100 patient-years and for SCD was 3.1 per patient-years (40% of CV deaths). The incidence of SCD preceded by HF hospitalization was greater than SCD without preceding HF hospitalization (P\u2009&amp;lt;\u20090.05). However, overall, SCD was less likely to be preceded by a non-fatal CV event compared to other causes of death: 9.6% of SCD events were preceded by an MI (vs. 46.6% for non-sudden CV death); 17.0% of SCD events were preceded with an HF hospitalization (vs. 25.4% for non-sudden CV death); and 2.7% of SCD events were preceded by stroke (vs.12.9% for non-sudden CV death).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Among patients with AMI complicated by HF, SCD, compared with other causes of death, was less likely to be preceded by a non-fatal CV event. As patients are less likely to have preceding non-fatal CV events to alert the healthcare team of a possible impending SCD event, additional strategies for risk stratification for SCD are needed.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ehjacc\/zuaa012","type":"journal-article","created":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T04:14:14Z","timestamp":1609474454000},"page":"127-131","source":"Crossref","is-referenced-by-count":5,"title":["Non-fatal cardiovascular events preceding sudden cardiac death in patients with an acute myocardial infarction complicated by heart failure: insights from the high-risk myocardial infarction database"],"prefix":"10.1093","volume":"10","author":[{"given":"Sonya K","family":"Hui","sequence":"first","affiliation":[{"name":"Division of Cardiology, McGill University Health Centre, Montreal, Canada"},{"name":"DREAM-CV Lab, McGill University Health Centre, Montreal, Canada"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2346-8330","authenticated-orcid":false,"given":"Abhinav","family":"Sharma","sequence":"additional","affiliation":[{"name":"Division of Cardiology, McGill University Health Centre, Montreal, Canada"},{"name":"DREAM-CV Lab, McGill University Health Centre, Montreal, Canada"}]},{"given":"Kieran","family":"Docherty","sequence":"additional","affiliation":[{"name":"University of Glasgow, BHF Cardiovascular Research Centre, Glasgow, UK"}]},{"given":"John J V","family":"McMurray","sequence":"additional","affiliation":[{"name":"University of Glasgow, BHF Cardiovascular Research Centre, Glasgow, UK"}]},{"given":"Bertram","family":"Pitt","sequence":"additional","affiliation":[{"name":"University of Michigan, Medicine, Ann Arbor, MI, USA"}]},{"given":"Kenneth","family":"Dickstein","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Stavanger University Hospital, Stavanger, Norway"}]},{"given":"Marc A","family":"Pfeffer","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, MA, USA"}]},{"given":"Nicolas","family":"Girerd","sequence":"additional","affiliation":[{"name":"National Institute of Health and Medical Research Center for Clinical Multidisciplinary Research, INSERM U1116, Universit\u00e9 de Lorraine, Inserm, Centre d\u2019Investigations cliniques-plurith\u00e9matique 1433, Inserm U1116; CHRU Nancy; F-CRIN INI-CRCT network, Nancy, France"}]},{"given":"Patrick","family":"Rossignol","sequence":"additional","affiliation":[{"name":"National Institute of Health and Medical Research Center for Clinical Multidisciplinary Research, INSERM U1116, Universit\u00e9 de Lorraine, Inserm, Centre d\u2019Investigations cliniques-plurith\u00e9matique 1433, Inserm U1116; CHRU Nancy; F-CRIN INI-CRCT network, Nancy, France"}]},{"given":"Jo\u00e3o Pedro","family":"Ferreira","sequence":"additional","affiliation":[{"name":"National Institute of Health and Medical Research Center for Clinical Multidisciplinary Research, INSERM U1116, Universit\u00e9 de Lorraine, Inserm, Centre d\u2019Investigations cliniques-plurith\u00e9matique 1433, Inserm U1116; CHRU Nancy; F-CRIN INI-CRCT network, Nancy, France"}]},{"given":"Faiez","family":"Zannad","sequence":"additional","affiliation":[{"name":"National Institute of Health and Medical Research Center for Clinical Multidisciplinary Research, INSERM U1116, Universit\u00e9 de Lorraine, Inserm, Centre d\u2019Investigations cliniques-plurith\u00e9matique 1433, Inserm U1116; CHRU Nancy; F-CRIN INI-CRCT network, Nancy, France"}]}],"member":"286","published-online":{"date-parts":[[2020,8,28]]},"reference":[{"key":"2021072111593295700_zuaa012-B1","first-page":"e272","article-title":"2017 AHA\/ACC\/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death","volume":"138","author":"Al-Khatib","year":"2018","journal-title":"Circulation"},{"key":"2021072111593295700_zuaa012-B2","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1056\/NEJMoa043938","article-title":"Sudden death in patients with myocardial infarction and left ventricular dysfunction, heart failure, or both","volume":"352","author":"Solomon","year":"2005","journal-title":"N Engl J Med"},{"key":"2021072111593295700_zuaa012-B3","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1002\/ejhf.1694","article-title":"Predictors of sudden cardiac death in high-risk patients following a myocardial infarction","volume":"22","author":"Docherty","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2021072111593295700_zuaa012-B4","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.pcad.2011.10.001","article-title":"The high-risk myocardial infarction database initiative","volume":"54","author":"Dickstein","year":"2012","journal-title":"Prog Cardiovasc Dis"},{"key":"2021072111593295700_zuaa012-B5","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1056\/NEJMoa032292","article-title":"Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both","volume":"349","author":"Pfeffer","year":"2003","journal-title":"N Engl J Med"},{"key":"2021072111593295700_zuaa012-B6","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N Engl J Med"},{"key":"2021072111593295700_zuaa012-B7","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/S0002-9149(98)00898-4","article-title":"Comparison of the effects of losartan and captopril on mortality in patients after acute myocardial infarction: the OPTIMAAL trial design. Optimal Therapy in Myocardial Infarction with the Angiotensin II Antagonist Losartan","volume":"83","author":"Dickstein","year":"1999","journal-title":"Am J Cardiol"},{"key":"2021072111593295700_zuaa012-B8","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/S1388-9842(00)00098-2","article-title":"Design and methodology of the CAPRICORN trial\u2014a randomised double blind placebo controlled study of the impact of carvedilol on morbidity and mortality in patients with left ventricular dysfunction after myocardial infarction","volume":"2","author":"Dargie","year":"2000","journal-title":"Eur J Heart Fail"},{"key":"2021072111593295700_zuaa012-B9","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/S0140-6736(00)04560-8","article-title":"Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial","volume":"357","author":"Dargie","year":"2001","journal-title":"Lancet"},{"key":"2021072111593295700_zuaa012-B10","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1016\/j.jacc.2015.10.036","article-title":"Design of major randomized trials: part 3 of a 4-part series on statistics for clinical trials","volume":"66","author":"Pocock","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"2021072111593295700_zuaa012-B11","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1002\/ejhf.1541","article-title":"Association of diabetes and kidney function according to age and systolic function with the incidence of sudden cardiac death and non-sudden cardiac death in myocardial infarction survivors with heart failure","volume":"21","author":"Coiro","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2021072111593295700_zuaa012-B12","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1002\/ejhf.1192","article-title":"Implantable cardioverter-defibrillators in heart failure patients with reduced ejection fraction and diabetes","volume":"20","author":"Sharma","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2021072111593295700_zuaa012-B13","doi-asserted-by":"crossref","first-page":"2680","DOI":"10.1016\/j.jacc.2018.03.523","article-title":"Using digital health technology to better generate evidence and deliver evidence-based care","volume":"71","author":"Sharma","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2021072111593295700_zuaa012-B14","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1056\/NEJMoa1609758","article-title":"Declining risk of sudden death in heart failure","volume":"377","author":"Shen","year":"2017","journal-title":"N Engl J Med"},{"key":"2021072111593295700_zuaa012-B15","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1056\/NEJMoa1800781","article-title":"Wearable cardioverter-defibrillator after myocardial infarction","volume":"379","author":"Olgin","year":"2018","journal-title":"N Engl J Med"},{"key":"2021072111593295700_zuaa012-B16","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1016\/j.jcmg.2019.05.034","article-title":"Structural and physiological imaging to predict the risk of lethal ventricular arrhythmias and sudden death","volume":"12","author":"Malhotra","year":"2019","journal-title":"JACC Cardiovasc Imaging"}],"container-title":["European Heart Journal. Acute Cardiovascular Care"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ehjacc\/article-pdf\/10\/2\/127\/39201222\/zuaa012.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ehjacc\/article-pdf\/10\/2\/127\/39201222\/zuaa012.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,21]],"date-time":"2021-07-21T12:01:24Z","timestamp":1626868884000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjacc\/article\/10\/2\/127\/5898156"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,28]]},"references-count":16,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2020,8,28]]},"published-print":{"date-parts":[[2021,4,8]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjacc\/zuaa012","relation":{},"ISSN":["2048-8726","2048-8734"],"issn-type":[{"value":"2048-8726","type":"print"},{"value":"2048-8734","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,2,1]]},"published":{"date-parts":[[2020,8,28]]}}}